SCHEMBL10127293

SCHEMBL10127293

CCc1nc(C(N)=O)c(Nc2ccccc2S(C)(=O)=O)nc1Cl

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 5/20 0.44
EML4 Q9HC35 2/20 0.43
CDK7 P50613 2/20 0.41
CDK9 P50750 2/20 0.41
TYK2 P29597 6/20 0.39
JAK2 O60674 5/20 0.39
JAK3 P52333 4/20 0.39
JAK1 P23458 4/20 0.39
PTK2 Q05397 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPK8 P45983 1/20 0.36
INSR P06213 1/20 0.36
IGF1R P08069 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
PLK1 P53350 1/20 0.36
CCNA1 P78396 1/20 0.36
SYK P43405 1/20 0.35
EPHB4 P54760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10127282 0.82 CCNA2 (0.42) SMN1; SMN2CCNA2CDK2PLK1CCNA1
SCHEMBL10126675 0.81 ALDH1A1 (0.50) SMN1; SMN2SYK
SCHEMBL10128965 0.79 ALK (0.70) ALKEML4
SCHEMBL282474 0.79 JAK3 (0.49) ALKEML4TYK2JAK2JAK3
SCHEMBL283230 0.78 EML4 (0.66) ALKEML4TYK2JAK2JAK3
SCHEMBL10157039 0.76 PTK2 (0.44) ALKEML4CDK7CDK9TYK2
SCHEMBL328224 0.75 EML4 (0.41) ALKEML4SYK
SCHEMBL10156685 0.75 PTK2 (0.43) ALKCDK7CDK9PTK2SMN1; SMN2
SCHEMBL10157680 0.75 ALK (0.44) ALKEML4
SCHEMBL10127286 0.73 MAPT (0.45) ALKEML4SMN1; SMN2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
WO-2010128659-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND アステラス製薬株式会社 (JP) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALK 2/4885EML4 1/4885CDK7 952/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALK 2/4885EML4 1/4885CDK7 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.